Capricor Shares Decline Following deramiocel Clinical Study Results

Key Facts

1Capricor shares declined after open-label extension (OLE) data for deramiocel failed to resolve regulatory concerns.

Capricor Therapeutics shares declined after open-label extension data for its drug deramiocel failed to resolve regulatory concerns. Seeking Alpha reported that the market reacted negatively to the long-term results for the Duchenne muscular dystrophy treatment, as the data did not provide the definitive clarity needed to mitigate existing hurdles for approval.

The stock experienced a downward move during trading on Monday, October 5, 2026, as investors appeared hesitant regarding the candidate's path to US FDA approval. This decline highlights the ongoing sensitivity in the biotech sector toward clinical trial outcomes and their impact on regulatory expectations.